Download pdf
The Evolution and Impact of Animal Vaccines: Advancements, Applications, and Future Directions
- 1 Department of Animal Sciences, Gansu Agriculture University, Gansu, China
* Author to whom correspondence should be addressed.
Abstract
Animal vaccines play a significant role in preventing and controlling animal infectious diseases, ensuring public health, and promoting the economic development of the livestock industry. This paper reviews the historical development of animal vaccines and explores their role in public health, the livestock economy, and the prevention and control of zoonotic diseases. It details several common types of animal vaccines, including inactivated vaccines, live attenuated vaccines, subunit vaccines, and mRNA vaccines, describing their preparation methods, immune mechanisms, and advantages and disadvantages. Additionally, the paper outlines the current application status of vaccines for three major animal infectious diseases: swine fever, bovine tuberculosis, and avian influenza. It also analyzes the development trends of new vaccine technologies, such as genetic engineering vaccines, nanoparticle vaccines, and oral and spray vaccines. Despite significant advances in vaccine technology, challenges remain, such as pathogen variation, technical and economic barriers, and issues related to regulation and quality control. This paper aims to provide direction for future research, emphasizing the importance of continuous technological innovation and a globally unified regulatory system. The goal is to develop new vaccines with stronger immunogenicity, fewer side effects, and better adaptability to pathogen variations, thereby enhancing the application effectiveness of animal vaccines in public health and the livestock industry.
Keywords
Animal Vaccines, Infectious Disease Control, Zoonotic Diseases, Vaccine Development Trends, mRNA Vaccines Introduction.
[1]. Zhang, G. (2017). Animal immune potential and new concept vaccine. Journal of Zhengzhou University (Natural Science Edition), 49(3), 123-126.
[2]. Meeusen, E. N. T., Walker, J., Peters, A., et al. (2007). Current status of veterinary vaccines. Clinical Microbiology Reviews, 20(3), 489-510.
[3]. Biggs, P. M. (1990). Vaccines and vaccination—past, present and future. British Poultry Science, 31(1), 3-22.
[4]. Pastoret, P. P., & Jones, P. (2004). Veterinary vaccines for animal and public health. Developments in Biologicals, 119.
[5]. Monath, T. P. (2013). Vaccines against diseases transmitted from animals to humans: a one health paradigm. Vaccine, 31(46), 5321-5338.
[6]. Alexandersen, S. (1996). Advantages and disadvantages of using live vaccines risks and control measures. Acta Veterinaria Scandinavica Supplementum, 90, 89-100.
[7]. Roth, J. A., & Henderson, L. M. (2001). New technology for improved vaccine safety and efficacy. Veterinary Clinics of North America: Food Animal Practice, 17, 585-597.
[8]. Crisci, E., Bárcena, J., & Montoya, M. (2012). Virus-like particles: the new frontier of vaccines for animal viral infections. Veterinary Immunology and Immunopathology, 148(3-4), 211-225.
[9]. Kallen, K. J., & Andreas, T. (2014). A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Therapeutic Advances in Vaccines, 2(1), 10-31.
[10]. Garcia-Beato, R., Salas, M. L., Vinuela, E., & Salas, J. (1992). Role of the host cell nucleus in the replication of African swine fever virus DNA. Virology, 188, 637–649.
[11]. Rojo, G., Garcia-Beato, R., Vinuela, E., Salas, M. L., & Salas, J. (1999). Replication of African swine fever virus DNA in infected cells. Virology, 257, 524–536.
[12]. Rock, D. L. (2017). Challenges for African swine fever vaccine development—“… perhaps the end of the beginning.” Veterinary Microbiology, 206, 52-58.
[13]. Galindo, I., & Alonso, C. (2017). African swine fever virus: a review. Viruses, 9(5), 103.
[14]. Muñoz‐Pérez, C., Jurado, C., & Sánchez‐Vizcaíno, J. M. (2012). African swine fever vaccine: turning a dream into reality. Transboundary and Emerging Diseases, 68(5), 2657-2668.
[15]. O'Reilly, L. M., & Daborn, C. J. (1995). The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tubercle and Lung Disease, 76, 1-46.
[16]. Michel, A. L., Müller, B., & Van Helden, P. D. (2010). Mycobacterium bovis at the animal–human interface: A problem, or not? Veterinary Microbiology, 140(3-4), 371-381.
[17]. Srinivasan, S., Conlan, A. J. K., Easterling, L. A., et al. (2021). A meta-analysis of the effect of Bacillus Calmette-Guérin vaccination against bovine tuberculosis: is perfect the enemy of good? Frontiers in Veterinary Science, 8, 637580.
[18]. Yang, J., Liu, Y., Huang, H., et al. (2012). Research progress of bovine tuberculosis vaccine. Animal Husbandry and Veterinary Medicine, 39(8), 212-214.
[19]. Palmer, M. V., Thacker, T. C., Waters, W. R., Robbe-Austerman, S., Lebepe-Mazur, S. M., & Harris, N. B. (2010). Persistence of Mycobacterium bovis Bacillus Calmette-Guérin in white-tailed deer (Odocoileus Virginianus) after oral or parenteral vaccination. Zoonoses and Public Health, 57, e206–e212.
[20]. Beltrán-Beck, B., de la Fuente, J., Garrido, J. M., et al. (2014). Oral vaccination with heat-inactivated Mycobacterium bovis activates the complement system to protect against tuberculosis. PLoS ONE, 9, e98048.
[21]. Garrido, J. M., Sevilla, I. A., Beltrán-Beck, B., et al. (2011). Protection against tuberculosis in Eurasian wild boar vaccinated with heat-inactivated Mycobacterium bovis. PLoS ONE, 6, e24905.
[22]. Gonzalo-Asensio, J., Marinova, D., Martin, C., & Aguilo, N. (2017). MTBVAC: Attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic. Frontiers in Immunology, 8, 1803.
[23]. Vordermeier, H. M., Villareal-Ramos, B., Cockle, P. J., et al. (2009). Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infection and Immunity, 77, 3364–3373.
[24]. Parlane, N. A., Shu, D., Subharat, S., et al. (2014). Revaccination of cattle with bacille Calmette-Guérin two years after first vaccination when immunity has waned, boosted protection against challenge with Mycobacterium bovis. PLoS ONE, 9, e106519.
[25]. Buddle, B. M., Wedlock, D. N., Denis, M., Vordermeier, H. M., & Hewinson, R. G. (2011). Update on vaccination of cattle and wildlife populations against tuberculosis. Veterinary Microbiology, 151, 14–22.
[26]. Biffar, L., Blunt, L., Atkins, W., et al. (2020). Evaluating the sensitivity of the bovine BCG challenge model using a prime boost Ad85A vaccine regimen. Vaccine, 38, 1241–1248.
[27]. Balseiro, A., Thomas, J., Gortázar, C., & Risalde, M. A. (2020). Development and challenges in animal tuberculosis vaccination. Pathogens, 9, 472.
[28]. Peiris, J. S. M., De Jong, M. D., & Guan, Y. (2007). Avian influenza virus (H5N1): a threat to human health. Clinical Microbiology Reviews, 20(2), 243-267.
[29]. Capua, I., & Alexander, D. J. (2004). Avian influenza: recent developments. Avian Pathology, 33(4), 393-404.
[30]. Alexander, D. J. (2000). A review of avian influenza in different bird species. Veterinary Microbiology, 74(1-2), 3-13.
[31]. Treanor, J. (2004). Influenza vaccine—outmaneuvering antigenic shift and drift. New England Journal of Medicine, 350(3), 218-220.
[32]. Blagodatski, A., Trutneva, K., Glazova, O., et al. (2021). Avian influenza in wild birds and poultry: dissemination pathways, monitoring methods, and virus ecology. Pathogens, 10, 630.
[33]. Huang, P., Sun, L., Li, J., et al. (2023). Potential cross-species transmission of highly pathogenic avian influenza H5 subtype (HPAI H5) viruses to humans calls for the development of H5-specific and universal influenza vaccines. Cell Discovery, 9(1), 58.
[34]. Sun, Y. (2018). Research and application of genetic engineering vaccines. Biochemical Engineering, 4(6), 152-153.
[35]. Singh, A., Misra, R., Mohanty, C., & Sahoo, S. K. (2010). Applications of nanotechnology in vaccine delivery. International Journal of Green Nanotechnology: Biomedicine, 2(1), B25–B45.
[36]. Bakke, H., et al. (2006). Oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scandinavian Journal of Immunology, 63(3), 223-231.
[37]. Buckland, B. C. (2005). The process development challenge for a new vaccine. Nature Medicine, 11(Suppl 4), S16-S19.
Cite this article
Huang,Z. (2024). The Evolution and Impact of Animal Vaccines: Advancements, Applications, and Future Directions. Theoretical and Natural Science,62,1-11.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 4th International Conference on Biological Engineering and Medical Science
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).